title: Effects of PGI2 and TxA2 analogs and inhibitors in orthodontic tooth movement.
abstract: This study evaluates the effects of prostacyclin (PGI2) and thromboxane A2 (TxA2) in orthodontic tooth movement and osteoclastic activity in rats. The study sample consisted of 150 male Sprague-Dawley rats. The rats were randomly divided into five equal groups, and each group was again equally divided into three subgroups (SGs). Twenty grams of reciprocal force was applied to maxillary incisors of the rats with a spring bent from 0.35 mm stainless steel wire, except for the rats in the last SG. Iloprost (PGI2 analog), indomethacin (PGI2 inhibitor), U 46619 (TxA2 analog), and imidazole (TxA2 inhibitor) were dissolved in 0.9% NaCl (saline solution), and each material was prepared in three different concentrations (10(-4), 10(-5), and 10(-6) M/L). Iloprost was administered (20 microL/12 hours) in the first three SGs with the sequence of 10(-4), 10(-5), and 10(-6) M/L. Indomethacin, U 46619, and imidazole were administered in the next nine SGs with the same sequence and dose. In SG 13, 0.9% NaCl solution was administered (20 microL/ 12 hours) to the rats together with orthodontic force. Only orthodontic force was not used in SG 14, and neither any solution nor orthodontic force was used in the last SG. The rats were sacrificed on the fifth day of the experiment, premaxillae were dissected, and cross samples were taken. The results showed that PGI2 and TxA2 analogs increased the number of multinuclear osteoclasts, osteoclastic bone resorption, and rate of orthodontic tooth movement.
authors.affiliation: Department of Orthodontics, Dental Sciences Center, Gulhane Military Medical Academy, Ankara, Turkey. holmez60@hotmail.com
authors.forename: Arif Umit
authors.initials: AU
authors.lastname: Gurton
authors.forename: Erol
authors.initials: E
authors.lastname: Akin
authors.forename: Deniz
authors.initials: D
authors.lastname: Sagdic
authors.forename: Huseyin
authors.initials: H
authors.lastname: Olmez
mesh_terms: D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid / Q000494:pharmacology; D000818:Animals; D011464:Epoprostenol / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors* / Q000096:biosynthesis; D016285:Iloprost / Q000494:pharmacology; D007093:Imidazoles / Q000494:pharmacology; D007213:Indomethacin / Q000494:pharmacology; D008297:Male; D010010:Osteoclasts / Q000187:drug effects; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D018709:Statistics, Nonparametric; D013928:Thromboxane A2 / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors*; D014087:Tooth Movement Techniques
chemical_list: D007093:Imidazoles; D013928:Thromboxane A2; D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; D011464:Epoprostenol; D016285:Iloprost; D007213:Indomethacin